This website is using cookies to provide a good browsing experience. These include essential cookies that are necessary for the operation of the site, as well as others that are used for anonymous statistical purposes.

This website is using cookies to provide a good browsing experience. These include essential cookies that are necessary for the operation of the site, as well as others that are used for anonymous statistical purposes.

Your cookie preferences have been saved.
Press Release - March 28, 2023

Our Technology

At ATANIS Biotech, we develop cutting-edge technologies to functionally assess allergic reactions safely in a test tube.

Explore

Our vision

At ATANIS Biotech, our mission is to revolutionize the way allergies are diagnosed and thereby improve treatment success and quality of life.

Read more

Our service

At ATANIS Biotech, we will provide diagnostic and scientific support to clinicians as well as researchers.

Explore

Our story

ATANIS Biotech AG has been incorporated in 2021 by four ambitious and visionary co-founders, who bring over 70 years of combined experience in clinical allergy research and diagnostic assay development to the company.

Latest news

Press Release - March 28, 2023

ATANIS has successfully completed a significant capital increase, moved to a new location and has hired new key personnel. iXLife a venture capital fund from France co-led the financing round with US-based AllerFund, the first and only venture capital firm focused on social impact in the food allergy space. Additional investments came from experienced private biotech…